Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prestige Consumer HealthcarePBH -2.24%69 PEG Ratio is 1.04 as of Aug. 20, 2026, which is 34% below its 10-year median of 1.57. GuruFocus rates PBH with a GF Score™ of 69/100 and a GF Value™ of $70.51 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 345 Drug Manufacturers companies, Prestige Consumer Healthcare ranks better than 66.38% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Prestige Consumer Healthcare's PEG Ratio or its related term are showing as below:
PBH'
s PEG Ratio Range Over the Past 10 Years
Min: 0.47 Med: 1.57 Max: 16.23
Current: 1.04
During the past 13 years, Prestige Consumer Healthcare's highest PEG Ratio was 16.23. The lowest was 0.47. And the median was 1.57.
PBH's PEG Ratio is ranked better than 66.38% of 345
companies
in the Drug Manufacturers industry
Industry Median: 1.81
vs PBH: 1.04
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Prestige Consumer Healthcare (NYSE:PBH) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Prestige Consumer Healthcare PEG Ratio Related Terms
Prestige Consumer Healthcare PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prestige Consumer Healthcare PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Prestige Consumer Healthcare's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Prestige Consumer Healthcare (PBH) has a PEG Ratio of 1.04 as of Aug. 20, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Prestige Consumer Healthcare and its competitors. This is 34% below median its historical median of 1.57. Over the past decade, Prestige Consumer Healthcare's PEG Ratio has ranged from 0.47 to 16.23. According to the industry distribution chart, Prestige Consumer Healthcare ranks #116 out of 345 companies in the Drug Manufacturers industry, placing it in the top 33.6%.
Is Prestige Consumer Healthcare's PEG Ratio too high?
Prestige Consumer Healthcare's current PEG Ratio of 1.04 is 34% below median its 10-year median of 1.57. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 16.23. The Drug Manufacturers industry median PEG Ratio is 1.81. Prestige Consumer Healthcare's value of 1.04 is 42.5% below this industry median. Based on the distribution chart, Prestige Consumer Healthcare ranks #116 out of 345 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Prestige Consumer Healthcare has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's PEG Ratio compare to BCRX and AMLX?
According to the Drug Manufacturers industry distribution chart, Prestige Consumer Healthcare ranks #116 out of 345 companies for PEG Ratio. This puts Prestige Consumer Healthcare in the upper half of its industry. The industry median PEG Ratio is 1.81. Prestige Consumer Healthcare's value of 1.04 is 42.5% below this benchmark. Historically, Prestige Consumer Healthcare's own PEG Ratio has ranged from 0.47 to 16.23 over the past decade. While the company's 10-year median is 1.57 vs. the industry median of 1.81, Prestige Consumer Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.81, based on 345 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prestige Consumer Healthcare's current PEG Ratio of 1.04 is 42.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Prestige Consumer Healthcare and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prestige Consumer Healthcare's current PEG Ratio is 1.04, which is 34% below median its own 10-year median of 1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (PBH) is currently considered Modestly Undervalued. The stock's GF Value™ is $70.51, compared to a current price of $50.52 — trading 28.4% below its estimated fair value. The current PEG Ratio is 1.04, which is 34% below median its 10-year median of 1.57 and 42.5% below the Drug Manufacturers industry median of 1.81. Prestige Consumer Healthcare's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Prestige Consumer Healthcare (PBH), the current PEG Ratio is 1.04 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prestige Consumer Healthcare (PBH) Overvalued in 2026?
Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued.
The current stock price of $50.52 is trading 28.4% below its estimated GF Value™ of $70.51.
GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.
Key valuation signals for PBH:
PEG Ratio: 1.04 (34% below median its 10-year median of 1.57)
GF Value™: $70.51 vs. price of $50.52 (28.4% below fair value)
Industry Position: 42.5% below the Drug Manufacturers median (#116 of 345)
No single metric tells the full story. See the PBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
69GF Score
Get the complete analysis for PBH
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBH has been successfully added to your 
